Hollis-Eden gets new HHS date on award |
|
|
|
Published
:
Thu, 01 Feb 2007 16:41
|
SAN DIEGO (AFX) - Drug developer Hollis-Eden Pharmaceuticals Inc. said Thursday the Department of Health and Human Services set a contract award date for which its radiation sickness drug under development is a candidate.The agency revised its award date to March 7. Previously, Hollis-Eden expected a decision by Jan. 31, and prior to that, by the end of September.The company previously said its drug Neumune is in the lead for a bid by the agency under the government's Project BioShield program. The program aims to develop a stockpile of treatments to be used in case of a nuclear or chemical attack. Neumune is aimed at treating overexposure to radiation sickness, or acute radiation syndrome.Hollis-Eden conducted late-stage trials of Neumune in 2006.Shares of fell 28 cents, or 5.3 percent, to $5.07 on the Nasdaq in morning trading. The stock has traded between $4.09 and $7.49 over the last 52 weeks.Copyright 2006 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
Print this Story
Nike to take colleges on tour of Asia 